CJD drug shows signs of success
Main Category: CJD / vCJD / Mad Cow DiseaseArticle Date: 14 Dec 2004 - 17:00 PDT
| Patient / Public: | ![]() |
3 (2 votes) |
| Healthcare Prof: | ![]() |
A patient suffering from Creutzfeld-Jakob disease (vCJD), the human form of BSE, has reportedly become the first person to contract the disease to be no longer regarded as terminally ill.
Jonathan Simms, 20, from Belfast, Northern Ireland, has been taking an experimental drug, pentosan polysulphate.
Mr Simms was diagnosed with the brain wasting disease three years ago and was given only months to live, but his parents eventually won a legal battle in the High Courts in Belfast and London in order to allow him to take the new drug. He is now the longest known survivor of vCJD and the first sufferer to begin taking the drug.
Pentosan polysulphate is a blood-thinning and anti-inflammatory drug, which had previously only been tested on animals. Mr Simms father, Don, discovered its existence whilst carrying out research on the Internet.
"Jonathan is very stable," Don Simms told BBC Radio Ulster. "The general consensus is that Jonathan Simms is no longer terminally ill. He is no longer in the last days or weeks of life - we hope they [the doctors] are right."
After two spells in a Northern Ireland hospital where a top neurosurgeon infused the drug directly into his brain, Mr Simms has been cared for by his parents and medical staff at his home in West Belfast.
http://www.hda-online.org.uk
Visit our cjd / vcjd / mad cow disease section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/17783.php>
APA
http://www.medicalnewstoday.com/releases/17783.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




